$20.05
6.31% day before yesterday
Nasdaq, Dec 27, 10:00 pm CET
ISIN
US45783C1018
Symbol
TIL
Sector
Industry

Instil Bio Inc Stock price

$20.05
-9.65 32.49% 1M
+10.14 102.32% 6M
+12.43 163.12% YTD
+12.59 168.79% 1Y
-306.15 93.85% 3Y
-379.95 94.99% 5Y
-379.95 94.99% 10Y
Nasdaq, Closing price Fri, Dec 27 2024
-1.35 6.31%
ISIN
US45783C1018
Symbol
TIL
Sector
Industry

Key metrics

Market capitalization $130.84m
Enterprise Value $95.84m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 0.74
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-57.43m
Free Cash Flow (TTM) Free Cash Flow $-58.58m
Cash position $120.35m
EPS (TTM) EPS $-11.56
P/E forward negative
Short interest 10.03%
Show more

Is Instil Bio Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

Instil Bio Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

3 Analysts have issued a Instil Bio Inc forecast:

2x Buy
67%
1x Hold
33%

Analyst Opinions

3 Analysts have issued a Instil Bio Inc forecast:

Buy
67%
Hold
33%

Financial data from Instil Bio Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
- -
-
100%
- Direct Costs 3.93 3.93
15% 15%
-
-3.93 -3.93
15% 15%
-
- Selling and Administrative Expenses 37 37
9% 9%
-
- Research and Development Expense 13 13
78% 78%
-
-54 -54
48% 48%
-
- Depreciation and Amortization 3.93 3.93
15% 15%
-
EBIT (Operating Income) EBIT -57 -57
47% 47%
-
Net Profit -75 -75
62% 62%
-

In millions USD.

Don't miss a Thing! We will send you all news about Instil Bio Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Instil Bio Inc Stock News

Positive
Seeking Alpha
28 days ago
Instil Bio is a clinical-stage biotech focusing on personalized immunotherapy. SYN-2510 targets the promising PD-L1/VEGF oncology pathway. The company recently licensed assets from ImmuneOnco Biopharmaceuticals, retaining commercialization rights outside Greater China and enhancing its global market positioning. SYN-2510 is advancing to Phase 2 trials for NSCLC and TNBC, addressing a TAM foreca...
Positive
The Motley Fool
3 months ago
Summit Therapeutics' stock is way up in response to clinical trial results that suggest the cancer therapy it's developing could become the standard of care for lots of patients. Instil Bio stock soared because it's developing a bispecific antibody similar to the candidate that pushed up Summit Therapeutics.
Neutral
GlobeNewsWire
3 months ago
DALLAS and SHANGHAI, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (Nasdaq: TIL, "Instil") and ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKEX:1541, “ImmuneOnco”) announced today the global registrational strategy for the PD-L1xVEGF bispecific antibody SYN-2510/IMM2510 in combination with chemotherapy in front-line non-small cell lung cancer (NSCLC) and in front-line triple-negative b...
More Instil Bio Inc News

Company Profile

Instil Bio, Inc. is a clinical-stage biopharmaceutical company engages in developing cell therapy pipeline of autologous tumor infiltrating lymphocyte therapies for the treatment of patients with cancer. The company was founded in August 2018 and is headquartered in Dallas, TX.

Head office United States
CEO Bronson Crouch
Employees 49
Founded 2018
Website www.instilbio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today